{"transactions":[{"id":4614041,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-09","kind":"sale","planned":false,"acquired":false,"shares":28837,"price":7.13,"value":205607.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018."}],"balance_after":3885115,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":4614040,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":192500,"price":7.41,"value":1426425.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018."}],"balance_after":3913952,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":4614039,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":38500,"price":7.11,"value":273735.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,166 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 602 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 17,942 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 954 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 354 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4106452,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":3650,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":32263,"price":7.17,"value":231325.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018."}],"balance_after":4144952,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":3649,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":25131,"price":7.19,"value":180691.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018."}],"balance_after":4177215,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":3648,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-01","kind":"sale","planned":false,"acquired":false,"shares":29088,"price":7.06,"value":205361.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 881 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 455 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,556 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 720 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 268 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4202346,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":672082,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-31","kind":"sale","planned":false,"acquired":false,"shares":44259,"price":6.99,"value":309370.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018."}],"balance_after":4231434,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":672081,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-28","kind":"sale","planned":false,"acquired":false,"shares":3733,"price":7.01,"value":26168.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018."}],"balance_after":4275693,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":672080,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":38922,"price":7.2,"value":280238.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,179 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 608 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 18,139 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 964 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 358 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4279426,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":675135,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-26","kind":"sale","planned":false,"acquired":false,"shares":14569,"price":7.06,"value":102857.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018."}],"balance_after":4318348,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":675134,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":26522,"price":7.54,"value":199975.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018."}],"balance_after":4332917,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":675133,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":21623,"price":7.34,"value":158712.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 655 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 338 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10,077 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 535 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 199 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4359439,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":939519,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":6000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1577119},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939518,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":22500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5914197},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939517,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were issued upon conversion as follows:  556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314262},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939516,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"purchase","planned":false,"acquired":true,"shares":1112777,"price":18,"value":20029986.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact."}],"balance_after":10260064,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939515,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1577119,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact."}],"balance_after":9147287,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939514,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":5914197,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact."}],"balance_after":7570168,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939513,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1314262,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were issued upon conversion as follows:  556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 341,709 by MPM Asset Management LLC (\"MPM AM\"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM."}],"balance_after":1655971,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":1147533,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-05-15T21:33:28.000Z","date":"2025-05-13","kind":"sale","planned":false,"acquired":false,"shares":630191,"price":8.06,"value":5079339.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. (\"BV 2014\"),  22,386 by MPM BioVentures 2014 (B), L.P. (\"BV 2014(B)\"), 12,233 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 224,467 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 11,267 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 4,432 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\").  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2108594,"source":{"system":"sec-edgar","filing":"0001415889-25-013251","document":"form4-05152025_090523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000141588925013251/form4-05152025_090523.xml","form_type":"4"}},{"id":1334074,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T22:00:22.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":21787,"price":20.23,"value":440751.01,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 9,893 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014, 10,153 by BV 2018, 540 by BV 2018(B) and 200 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.01 to $20.595 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,989,368 by BV 2014, 132,687 by BV 2014(B), 68,475 by AM BV2014, 2,041,721 by BV 2018, 108,515 by BV 2018(B) and 40,296 by AM BV2018."}],"balance_after":4381062,"source":{"system":"sec-edgar","filing":"0001415889-24-029142","document":"form4-12122024_051204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000141588924029142/form4-12122024_051204.xml","form_type":"4"}},{"id":1334073,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T22:00:22.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":22935,"price":20.77,"value":476359.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 10,415 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 695 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 358 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10 688 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 568 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 211 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.356 to $21.315 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,999,261 by BV 2014, 133,347 by BV 2014(B), 68,816 by AM BV2014, 2,051,874 by BV 2018, 109,055 by BV 2018(B) and 40,496 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4402849,"source":{"system":"sec-edgar","filing":"0001415889-24-029142","document":"form4-12122024_051204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000141588924029142/form4-12122024_051204.xml","form_type":"4"}},{"id":2441782,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:13:37.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":18135,"price":42.03,"value":762214.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F13","text":"The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018 and 135 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are held as follows: 1,544,580 by BV 2014, 97,289 by BV 2014(B), 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B) and 19,263 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2738785,"source":{"system":"sec-edgar","filing":"0001209191-22-002169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919122002169/doc4.xml","form_type":"4"}},{"id":2441781,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:13:37.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":7671,"price":46.47,"value":356471.37,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by  BV 2018 and 53 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B) and 19,398 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2756920,"source":{"system":"sec-edgar","filing":"0001209191-22-002169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919122002169/doc4.xml","form_type":"4"}},{"id":2441780,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:13:37.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":6768,"price":45.32,"value":306725.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by BV 2018 and 41 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B) and 19,451 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2764591,"source":{"system":"sec-edgar","filing":"0001209191-22-002169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919122002169/doc4.xml","form_type":"4"}},{"id":2441779,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:13:37.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":19366,"price":43.2,"value":836611.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares were sold as follows: 11,534 by BV 2014, 390 by AM BV2014, 7,300 by BV 2018 and 142 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B) and 19,492 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2771359,"source":{"system":"sec-edgar","filing":"0001209191-22-002169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919122002169/doc4.xml","form_type":"4"}},{"id":2441778,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:13:37.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":94745,"price":42.05,"value":3984027.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,959 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 35,653 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 719 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 19,634 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2790725,"source":{"system":"sec-edgar","filing":"0001209191-22-002169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919122002169/doc4.xml","form_type":"4"}},{"id":2482443,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":1494,"price":34.11,"value":50960.34,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F24","text":"The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018 and 11 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F26","text":"The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172 by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B) and 20,353 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2885470,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482442,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":17962,"price":33.15,"value":595440.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F21","text":"The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018 and 134 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F23","text":"The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B) and 20,364 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2886964,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482441,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":60,"price":35.04,"value":2102.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F19","text":"The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018 and 1 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B) and 20,498 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2904926,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482440,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":508,"price":34.08,"value":17312.64,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F16","text":"The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018 and 4 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B) and 20,499 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2904986,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482439,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":1171,"price":33.57,"value":39310.47,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F13","text":"The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018 and 8 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are held as follows: 1,643,901 by BV 2014, 97,289 by BV 2014(B), 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B) and 20,503 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2905494,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482438,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":8469,"price":32.35,"value":273972.15,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F10","text":"The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by  BV 2018 and 63 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B) and 20,511 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2906665,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482437,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":179,"price":36.26,"value":6490.54,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by  BV 2018 and 1 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B) and 20,574 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2915134,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482436,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":2419,"price":35.44,"value":85729.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018 and 18 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B) and 20,575 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2915313,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2482435,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:36:44.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":17569,"price":34.68,"value":609292.92,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 359 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,612 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 131 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,651,193 by BV 2014, 97,289 by, 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by BV 2018(B) and 20,593 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2917732,"source":{"system":"sec-edgar","filing":"0001209191-21-068410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121068410/doc4.xml","form_type":"4"}},{"id":2489023,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":7430,"price":34.83,"value":258786.9,"ownership":{"direct":false,"nature":"See Fpotnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F20","text":"The shares were sold as follows: 4,427 by BV 2014, 152 by AM BV2014, 2,796 by BV 2018 and 55 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F22","text":"The shares are held as follows: 1,661,660 by BV 2014, 97,289 by BV 2014(B), 57,193 by AM BV2014, 1,049,469 by BV 2018, 48,966 by BV 2018(B) and 20,724 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2935301,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489022,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":29757,"price":33.74,"value":1004001.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 17,728 by BV 2014, 611 by AM BV2014, 11,197 by BV 2018 and 221 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 1,666,087 by BV 2014, 97,289 by BV 2014(B), 57,345 by AM BV2014, 1,052,265 by BV 2018, 48,966 by BV 2018(B) and 20,779 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2942731,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489021,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":896,"price":35.34,"value":31664.64,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 534 by BV 2014, 18 by AM BV2014, 337 by BV 2018 and 7 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,683,815 by BV 2014, 97,289 by BV 2014(B), 57,956 by AM BV2014, 1,063,462 by BV 2018, 48,966 by BV 2018(B) and 21,000 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2972488,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489020,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":5457,"price":34.61,"value":188866.77,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 3,251 by BV 2014, 112 by AM BV2014, 2,053 by  BV 2018 and 41 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,684,349 by BV 2014, 97,289 by BV 2014(B), 57,974 by AM BV2014, 1,063,799 by BV 2018, 48,966 by BV 2018(B) and 21,007 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2973384,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489019,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":6042,"price":33.82,"value":204340.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 3,600 by BV 2014, 124 by AM BV2014, 2,274 by  BV 2018 and 44 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,687,600 by BV 2014, 97,289 by BV 2014(B), 58,086 by AM BV2014, 1,065,852 by BV 2018, 48,966 by BV 2018(B) and 21,048 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2978841,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489018,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":28076,"price":35.19,"value":987994.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 16,733 by BV 2014, 576 by AM BV2014, 10,569 by BV 2018 and 198 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.93 to $35.465 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,691,200 by BV 2014, 97,289 by BV 2014(B), 58,210 by AM BV2014, 1,068,126 by BV 2018, 48,966 by BV 2018(B) and 21,092 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":2984883,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2489017,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:56:17.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":5861,"price":34.62,"value":202907.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,494 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 120 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,206 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 41 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.93 to $34.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,707,933 by BV 2014, 97,289 by, 58,786 by AM BV2014, 1,078,695 by BV 2018, 48,966 by BV 2018(B) and 21,290 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3012959,"source":{"system":"sec-edgar","filing":"0001209191-21-067707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067707/doc4.xml","form_type":"4"}},{"id":2492217,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:57:53.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":298,"price":35.37,"value":10540.26,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by  BV 2018 and 2 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B) and 21,331 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3018820,"source":{"system":"sec-edgar","filing":"0001209191-21-067150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067150/doc4.xml","form_type":"4"}},{"id":2492216,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:57:53.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":10073,"price":34.46,"value":347115.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by  BV 2018 and 75 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B) and 21,333 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3019118,"source":{"system":"sec-edgar","filing":"0001209191-21-067150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067150/doc4.xml","form_type":"4"}},{"id":2492215,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:57:53.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":6129,"price":36.03,"value":220827.87,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018 and 45 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B) and 21,408 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3029191,"source":{"system":"sec-edgar","filing":"0001209191-21-067150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067150/doc4.xml","form_type":"4"}},{"id":2492214,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:57:53.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":6545,"price":35.49,"value":232282.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 134 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,463 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 49 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,721,258 by BV 2014, 97,289 by, 59,245 by AM BV2014, 1,087,109 by BV 2018, 48,966 by BV 2018(B) and 21,453 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3035320,"source":{"system":"sec-edgar","filing":"0001209191-21-067150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121067150/doc4.xml","form_type":"4"}},{"id":2495615,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":13126,"price":37.02,"value":485924.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F23","text":"The shares were sold as follows: 7,820 by BV 2014, 269 by AM BV2014, 4,939 by BV 2018 and 98 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F24","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F25","text":"The shares are held as follows: 1,725,157 by BV 2014, 97,289 by BV 2014(B), 59,379 by AM BV2014, 1,089,572 by BV 2018, 48,966 by BV 2018(B) and 21,502 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3041865,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495614,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":18343,"price":36.05,"value":661265.15,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F20","text":"The shares were sold as follows: 10,929 by BV 2014, 376 by AM BV2014, 6,902 by BV 2018 and 136 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.83 to $36.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F22","text":"The shares are held as follows: 1,732,977 by BV 2014, 97,289 by BV 2014(B), 59,648 by AM BV2014, 1,094,511 by BV 2018, 48,966 by BV 2018(B) and 21,600 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3054991,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495613,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":4868,"price":35.2,"value":171353.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 2,900 by BV 2014, 100 by AM BV2014, 1,832 by BV 2018 and 36 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 1,743,906 by BV 2014, 97,289 by BV 2014(B), 60,024 by AM BV2014, 1,101,413 by BV 2018, 48,966 by BV 2018(B) and 21,736 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3073334,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495612,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":359,"price":36.5,"value":13103.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 214 by BV 2014, 7 by AM BV2014, 135 by  BV 2018 and 3 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,746,806  by BV 2014, 97,289 by BV 2014(B), 60,124 by AM BV2014, 1,103,245 by BV 2018, 48,966 by BV 2018(B) and 21,772 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3078202,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495611,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":19645,"price":36.21,"value":711345.45,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 11,704 by BV 2014, 403 by AM BV2014, 7,392 by  BV 2018 and 146 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,747,020 by BV 2014, 97,289 by BV 2014(B), 60,131 by AM BV2014, 1,103,380 by BV 2018, 48,966 by BV 2018(B) and 21,775 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3078561,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495610,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":11807,"price":37.81,"value":446422.67,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 7,034 by BV 2014, 242 by AM BV2014, 4,443 by BV 2018 and 88 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,758,724 by BV 2014, 97,289 by BV 2014(B), 60,534 by AM BV2014, 1,110,772 by BV 2018, 48,966 by BV 2018(B) and 21,921 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3098206,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495609,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":9307,"price":37.16,"value":345848.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 5,545 by BV 2014, 191 by AM BV2014, 3,502 by BV 2018 and 69 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $37.555 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,765,758 by BV 2014, 97,289 by, 60,776 by AM BV2014, 1,115,215 by BV 2018, 48,966 by BV 2018(B) and 22,009 by AM BV2018.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3110013,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2495608,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:35:58.000Z","date":"2021-11-17","kind":"other","acquired":false,"shares":15671,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata in-kind distribution from MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\") and MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") to its respectve limited partners for no consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were distributed as follows: 10,424 by BV 2014(B) and 5,247 by BV 2018(B)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,771,303 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 97,289 by BV2014(B), 60,967 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 1,118,717 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 48,966 by BV 2018(B) and 22,078 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018.  Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3119320,"source":{"system":"sec-edgar","filing":"0001209191-21-066853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121066853/doc4.xml","form_type":"4"}},{"id":2524702,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-11-04T21:38:21.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":3683241,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608  by BV 2018(B) and 4,682 by AM BV2018."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509024},"source":{"system":"sec-edgar","filing":"0001209191-21-062983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121062983/doc4.xml","form_type":"4"}},{"id":2524701,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-11-04T21:38:21.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":27617675,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 115,596 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 59,655 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 1,778,737 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 94,538 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 35,105 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.\n.."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3816760},"source":{"system":"sec-edgar","filing":"0001209191-21-062983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121062983/doc4.xml","form_type":"4"}},{"id":2524700,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T21:38:21.000Z","date":"2021-11-02","kind":"purchase","acquired":true,"shares":100000,"price":20,"value":2000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018."}],"balance_after":4425784,"source":{"system":"sec-edgar","filing":"0001209191-21-062983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121062983/doc4.xml","form_type":"4"}},{"id":2524699,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T21:38:21.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":509024,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608  by BV 2018(B) and 4,682 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018."}],"balance_after":4325784,"source":{"system":"sec-edgar","filing":"0001209191-21-062983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121062983/doc4.xml","form_type":"4"}},{"id":2524698,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T21:38:21.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":3816760,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 115,596 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 59,655 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 1,778,737 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 94,538 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 35,105 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.\n.."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021.  The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3816760,"source":{"system":"sec-edgar","filing":"0001209191-21-062983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121062983/doc4.xml","form_type":"4"}},{"id":2540707,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:35:53.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":6167,"price":27.14,"value":167372.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by  BV 2018 and 45 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B) and 22,078 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3134991,"source":{"system":"sec-edgar","filing":"0001209191-21-060724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060724/doc4.xml","form_type":"4"}},{"id":2540706,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:35:53.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":2039,"price":28.01,"value":57112.39,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018 and 15 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B) and 22,123 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3141158,"source":{"system":"sec-edgar","filing":"0001209191-21-060724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060724/doc4.xml","form_type":"4"}},{"id":2540705,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:35:53.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":8893,"price":27.53,"value":244824.29,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 182 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 3,347 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 66 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 22,138 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3143197,"source":{"system":"sec-edgar","filing":"0001209191-21-060724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060724/doc4.xml","form_type":"4"}},{"id":2542495,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:28:35.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":27320,"price":27.3,"value":745836.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 16,277 by BV 2014, 560 by AM BV2014, 10,280 by  BV 2018 and 203 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,781,492 by BV 2014, 107,713 by BV 2014(B), 61,316 by AM BV2014, 1,125,152 by BV 2018, 54,213 by BV 2018(B) and 22,204 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3152090,"source":{"system":"sec-edgar","filing":"0001209191-21-060491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060491/doc4.xml","form_type":"4"}},{"id":2542494,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:28:35.000Z","date":"2021-10-13","kind":"sale","acquired":false,"shares":20929,"price":27.13,"value":567803.77,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,469 by BV 2014, 429 by AM BV2014, 7,875 by BV 2018 and 156 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,797,769 by BV 2014, 107,713 by BV 2014(B), 61,876 by AM BV2014, 1,135,432 by BV 2018, 54,213 by BV 2018(B) and 22,407 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3179410,"source":{"system":"sec-edgar","filing":"0001209191-21-060491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060491/doc4.xml","form_type":"4"}},{"id":2542493,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:28:35.000Z","date":"2021-10-12","kind":"sale","acquired":false,"shares":8521,"price":27.09,"value":230833.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,077 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 175 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 3,206 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 63 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,810,238, by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 62,305 by AM BV2014, 1,143,307 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 22,563 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3200339,"source":{"system":"sec-edgar","filing":"0001209191-21-060491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060491/doc4.xml","form_type":"4"}},{"id":2544615,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:34:57.000Z","date":"2021-10-11","kind":"sale","acquired":false,"shares":48812,"price":27.24,"value":1329638.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by  BV 2018 and 363 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B) and 22,626 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3208860,"source":{"system":"sec-edgar","filing":"0001209191-21-060237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060237/doc4.xml","form_type":"4"}},{"id":2544614,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:34:57.000Z","date":"2021-10-08","kind":"sale","acquired":false,"shares":2032,"price":27.01,"value":54884.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018 and 15 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B) and 22,989 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3257672,"source":{"system":"sec-edgar","filing":"0001209191-21-060237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060237/doc4.xml","form_type":"4"}},{"id":2544613,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:34:57.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":1149,"price":27,"value":31023.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 684 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 24 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 432 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 9 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,845,606 ,by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 63,523 by AM BV2014, 1,165,645 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 23,004 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3259704,"source":{"system":"sec-edgar","filing":"0001209191-21-060237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121060237/doc4.xml","form_type":"4"}},{"id":2549363,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T20:33:29.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":20711,"price":27.06,"value":560439.66,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,339 by BV 2014, 425 by AM BV2014, 7,793 by BV 2018 and 154 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,846,290 by BV 2014, 107,713 by BV 2014(B), 63,547 by AM BV2014, 1,166,077 by BV 2018, 54,213 by BV 2018(B) and 23,013 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3260853,"source":{"system":"sec-edgar","filing":"0001209191-21-059430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121059430/doc4.xml","form_type":"4"}},{"id":2549362,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T20:33:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":6855,"price":27,"value":185085.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,084 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 141 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,579 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 51 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,858,629 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 63,972 by AM BV2014, 1,173,870 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 23,167 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3281564,"source":{"system":"sec-edgar","filing":"0001209191-21-059430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121059430/doc4.xml","form_type":"4"}},{"id":2555855,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-30T21:06:41.000Z","date":"2021-09-30","kind":"sale","acquired":false,"shares":2292,"price":27,"value":61884.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,366 by BV 2014, 47 by AM BV2014, 862 by BV 2018 and 17 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.955 to $27.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,862,713 by BV 2014, 107,713 by BV 2014(B), 64,113 by AM BV2014, 1,176,449 by BV 2018, 54,213 by BV 2018(B) and 23,218 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3288419,"source":{"system":"sec-edgar","filing":"0001209191-21-058210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121058210/doc4.xml","form_type":"4"}},{"id":2555854,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-30T21:06:41.000Z","date":"2021-09-28","kind":"sale","acquired":false,"shares":19214,"price":27,"value":518778.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 11,447 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 394 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,230 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 143 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,864,079 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 64,160 by AM BV2014, 1,177,311 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 23,235 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3290711,"source":{"system":"sec-edgar","filing":"0001209191-21-058210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121058210/doc4.xml","form_type":"4"}},{"id":2558973,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:52:28.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":11625,"price":27.09,"value":314921.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 6,926 by BV 2014, 238 by AM BV2014, 4,375 by  BV 2018 and 86 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,875,526 by BV 2014, 107,713 by BV 2014(B), 64,554 by AM BV2014, 1,184,541 by BV 2018, 54,213 by BV 2018(B) and 23,378 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3309925,"source":{"system":"sec-edgar","filing":"0001209191-21-057824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057824/doc4.xml","form_type":"4"}},{"id":2558972,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:52:28.000Z","date":"2021-09-24","kind":"sale","acquired":false,"shares":4913,"price":27.81,"value":136630.53,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 2,927 by BV 2014, 101 by AM BV2014, 1,849 by  BV 2018 and 36 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $28.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,882,452 by BV 2014, 107,713 by BV 2014(B), 64,792 by AM BV2014, 1,188,916 by BV 2018, 54,213 by BV 2018(B) and 23,464 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3321550,"source":{"system":"sec-edgar","filing":"0001209191-21-057824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057824/doc4.xml","form_type":"4"}},{"id":2558971,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:52:28.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":717,"price":28.38,"value":20348.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 427 by BV 2014, 15 by AM BV2014, 270 by BV 2018 and 5 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,885,379 by BV 2014, 107,713 by BV 2014(B), 64,893 by AM BV2014, 1,190,765 by BV 2018, 54,213 by BV 2018(B) and 23,500 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3326463,"source":{"system":"sec-edgar","filing":"0001209191-21-057824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057824/doc4.xml","form_type":"4"}},{"id":2558970,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:52:28.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":36213,"price":27.96,"value":1012515.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 21,575 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 743 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,626 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 269 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,885,806 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 64,908 by AM BV2014, 1,191,035 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 23,505 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":3327180,"source":{"system":"sec-edgar","filing":"0001209191-21-057824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057824/doc4.xml","form_type":"4"}},{"id":2561062,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:19:53.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":14294,"price":27.54,"value":393656.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 8,516 by BV 2014, 293 by AM BV2014, 5,379 by BV 2018 and 106 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 to $27.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,907,381 by BV 2014, 107,713 by BV 2014(B), 65,651 by AM BV2014, 1,204,661 by BV 2018, 54,213 by BV 2018(B) and 23,774 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3363393,"source":{"system":"sec-edgar","filing":"0001209191-21-057415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057415/doc4.xml","form_type":"4"}},{"id":2561061,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:19:53.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":19635,"price":27.47,"value":539373.45,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 11,698 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 403 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,388 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 146 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,915,897 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 65,944 by AM BV2014, 1,210,040 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 23,880 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3377687,"source":{"system":"sec-edgar","filing":"0001209191-21-057415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121057415/doc4.xml","form_type":"4"}},{"id":2564152,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:37:35.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":13701,"price":27.84,"value":381435.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 8,163 by BV 2014, 281 by AM BV2014, 5,156 by BV 2018 and 101 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $28.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,927,595 by BV 2014, 107,713 by BV 2014(B), 66,347 by AM BV2014, 1,217,428 by BV 2018, 54,213 by BV 2018(B) and 24,026 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3397322,"source":{"system":"sec-edgar","filing":"0001209191-21-056949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056949/doc4.xml","form_type":"4"}},{"id":2564151,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:37:35.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":10602,"price":27.03,"value":286572.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,317 by BV 2014, 217 by AM BV2014, 3,990 by BV 2018 and 78 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.535 to $27.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,935,758 by BV 2014, 107,713 by BV 2014(B), 66,628 by AM BV2014, 1,222,584 by BV 2018, 54,213 by BV 2018(B) and 24,127 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3411023,"source":{"system":"sec-edgar","filing":"0001209191-21-056949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056949/doc4.xml","form_type":"4"}},{"id":2564150,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:37:35.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":45698,"price":28.82,"value":1317016.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 27,226 by BV 2014, 937 by AM BV2014, 17,195 by BV 2018 and 340 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,942,075 by BV 2014, 107,713 by BV 2014(B), 66,845 by AM BV2014, 1,226 574 by BV 2018, 54,213 by BV 2018(B) and 24,205 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3421625,"source":{"system":"sec-edgar","filing":"0001209191-21-056949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056949/doc4.xml","form_type":"4"}},{"id":2564149,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:37:35.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":21253,"price":28.47,"value":605072.91,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 12,662 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 436 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,997 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 158 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,969,301 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 67,782 by AM BV2014, 1,243,769 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 24,545 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3467323,"source":{"system":"sec-edgar","filing":"0001209191-21-056949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056949/doc4.xml","form_type":"4"}},{"id":2567925,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:43.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":991,"price":28.15,"value":27896.65,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 591 by BV 2014, 20 by AM BV2014, 373 by BV 2018 and 7 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.13 to $28.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,981,963 by BV 2014, 107,713 by BV 2014(B), 68,218 by AM BV2014, 1,251,766 by BV 2018, 54,213 by BV 2018(B) and 24,703 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3488576,"source":{"system":"sec-edgar","filing":"0001209191-21-056413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056413/doc4.xml","form_type":"4"}},{"id":2567924,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:43.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":23113,"price":27.79,"value":642310.27,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 13,770 by BV 2014, 474 by AM BV2014, 8,697 by BV 2018 and 172 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.12 to $28.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,982,554 by BV 2014, 107,713 by BV 2014(B), 68,238 by AM BV2014, 1,252,139 by BV 2018, 54,213 by BV 2018(B) and 24,710 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3489567,"source":{"system":"sec-edgar","filing":"0001209191-21-056413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056413/doc4.xml","form_type":"4"}},{"id":2567923,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:43.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":3623,"price":27.99,"value":101407.77,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 2,159 by BV 2014, 74 by AM BV2014, 1,363 by BV 2018 and 27 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.055 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,996,324 by BV 2014, 107,713 by BV 2014(B), 68,712 by AM BV2014, 1,260,836 by BV 2018, 54,213 by BV 2018(B) and 24,882 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3512680,"source":{"system":"sec-edgar","filing":"0001209191-21-056413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056413/doc4.xml","form_type":"4"}},{"id":2567922,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:43.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":17938,"price":27.5,"value":493295.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 10,687 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 368 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,750 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 133 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.91 to $27.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,998,483 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 68,786 by AM BV2014, 1,262,199 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 24,909 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3516303,"source":{"system":"sec-edgar","filing":"0001209191-21-056413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121056413/doc4.xml","form_type":"4"}},{"id":2572135,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T22:59:39.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":21384,"price":27.64,"value":591053.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 12,740 by BV 2014, 439 by AM BV2014, 8,046 by BV 2018 and 159 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $27.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,009,170 by BV 2014, 107,713 by BV 2014(B), 69,154 by AM BV2014, 1,268,949 by BV 2018, 54,213 by BV 2018(B) and 25,042 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3534241,"source":{"system":"sec-edgar","filing":"0001209191-21-055741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055741/doc4.xml","form_type":"4"}},{"id":2572134,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T22:59:39.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":6771,"price":28.73,"value":194530.83,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 4,034 by BV 2014, 139 by AM BV2014, 2,547 by BV 2018 and 51 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.46 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,021,910 by BV 2014, 107,713 by BV 2014(B), 69,593 by AM BV2014, 1,276,995 by BV 2018, 54,213 by BV 2018(B) and 25,201 by AM BV2018.  The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3555625,"source":{"system":"sec-edgar","filing":"0001209191-21-055741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055741/doc4.xml","form_type":"4"}},{"id":2572133,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T22:59:39.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":6760,"price":27.86,"value":188333.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018 and 50 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B) and 25,252 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3562396,"source":{"system":"sec-edgar","filing":"0001209191-21-055741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055741/doc4.xml","form_type":"4"}},{"id":2572132,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T22:59:39.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":22725,"price":28.97,"value":658343.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 13,539 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 466 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 8,551 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 169 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,029,971 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 69,871 by AM BV2014, 1,282,086 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 25,302 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3569156,"source":{"system":"sec-edgar","filing":"0001209191-21-055741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055741/doc4.xml","form_type":"4"}},{"id":2576119,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T23:12:06.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":940,"price":29.1,"value":27354.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018 and 7 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B) and 25,471 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary\ninterest therein."}],"balance_after":3591881,"source":{"system":"sec-edgar","filing":"0001209191-21-055209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055209/doc4.xml","form_type":"4"}},{"id":2576118,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T23:12:06.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":11152,"price":28.61,"value":319058.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018 and 83 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B) and 25,478 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3592821,"source":{"system":"sec-edgar","filing":"0001209191-21-055209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055209/doc4.xml","form_type":"4"}},{"id":2576117,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T23:12:06.000Z","date":"2021-09-07","kind":"other","acquired":false,"shares":31340,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were distributed as follows: 20,848 by BV 2014(B) and 10,492 by AM BV 2018(B)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B) and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3603793,"source":{"system":"sec-edgar","filing":"0001209191-21-055209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055209/doc4.xml","form_type":"4"}},{"id":2576116,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T23:12:06.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":30474,"price":29.18,"value":889231.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 625 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 11,467 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 226 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3635313,"source":{"system":"sec-edgar","filing":"0001209191-21-055209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121055209/doc4.xml","form_type":"4"}},{"id":2750537,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:15:51.000Z","date":"2021-04-09","kind":"sale","acquired":false,"shares":119,"price":29.99,"value":3568.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 71 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 45 by MPM BioVentures 2018, L.P. (\"BV 2018\") and 1 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 2,068,870 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 71,210 by AM BV2014, 1,306,654 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") and 25,787 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3665787,"source":{"system":"sec-edgar","filing":"0001209191-21-026435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121026435/doc4.xml","form_type":"4"}},{"id":2752208,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:09:19.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":247,"price":31.01,"value":7659.47,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 147 by BV 2014, 5 by AM BV2014, 93 by BV 2018 and 2 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.945 to\n$31.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 2,068,941 by BV 2014, 128,561 by BV 2014(B), 71,212 by AM BV2014, 1,306,699 by BV 2018, 64,705 by BV 2018(B) and 25,788 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary\ninterest therein."}],"balance_after":3655906,"source":{"system":"sec-edgar","filing":"0001209191-21-026212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121026212/doc4.xml","form_type":"4"}},{"id":2752207,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:09:19.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":19057,"price":30.51,"value":581429.07,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 11,354 by BV 2014, 391 by AM BV2014, 7,171 by BV 2018 and 141 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to\n$30.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 2,069,088 by BV 2014, 128,561 by BV 2014(B), 71,217 by AM BV2014, 1,306,792 by BV 2018, 64,705 by BV 2018(B) and 25,790 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3666153,"source":{"system":"sec-edgar","filing":"0001209191-21-026212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121026212/doc4.xml","form_type":"4"}},{"id":2752206,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:09:19.000Z","date":"2021-04-07","kind":"other","acquired":false,"shares":15670,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were distributed as follows: 10,424 by BV 2014(B) and 5,246 by AM BV 2018(B)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,080,442 by BV 2014, 128,561 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 64,705 by BV 2018(B) and 25,931 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3685210,"source":{"system":"sec-edgar","filing":"0001209191-21-026212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121026212/doc4.xml","form_type":"4"}},{"id":2752205,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:09:19.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":777,"price":33.84,"value":26293.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 463 by BV 2014, 16 by AM BV2014, 292 by  BV 2018 and 6 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,080,442 by BV 2014, 138,985 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 69,951 by BV 2018(B) and 25,931 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":3700880,"source":{"system":"sec-edgar","filing":"0001209191-21-026212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000120919121026212/doc4.xml","form_type":"4"}}],"next_cursor":"2021-04-09T20:09:19.000000Z,2752205"}